Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Sarcoma 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 16pembrolizumab 14Radiosurgery 7Nivolumab 5Celecoxib 5poly ICLC 4Radiation 4Injections 4Radiotherapy 3Melphalan 3Ipilimumab 3Filgrastim 3Etoposide 3Docetaxel 3Cryosurgery 3Blood Specimen Collection 3Biopsy 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2fludarabine 2durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Transurethral Resection of Prostate 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × AP 1903 reagent × Dermatologic × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡